跳至主要内容
临床试验/NCT04950192
NCT04950192已完成不适用

The Philips (VeriSight) Intracardiac Echocardiography (ICE) Registry

Philips Clinical & Medical Affairs Global5 个研究点 分布在 1 个国家目标入组 155 人开始时间: 2021年10月25日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
155
试验地点
5
主要终点
Technical Success

研究概览

简要总结

The purpose of this observational registry is to report real-world safety and performance of VeriSight for ultrasound guided ICE imaging in percutaneous cardiac intervention procedures when used in standard clinical practice.

详细描述

This is a prospective, multi-center, observational, single-arm registry intended to gather real-world data to report VeriSight ICE catheter performance and safety. It will be conducted in the United States under the approval of one or more recognized institutional review boards and in compliance with Good Clinical Practice guidelines defined in International Standards Organization:14155;2011, the Declaration of Helsinki, and all applicable federal and local laws and regulations. Only on label uses of the VeriSight ICE catheter will be allowed. No specific claims are being validated during this registry, though data analyzed from this protocol are intended to inform of future claims regarding the performance and safety of the VeriSight catheter.

Enrolled patients will be imaged with VeriSight for various types of percutaneous cardiac interventional procedures. Enrolled subjects will be followed until discharge or ≤48 hrs post-procedure. The registry has a planned duration of approximately 24-36 months with interim analysis planned at 100 patients before further enrollment will be considered. Statistical hypotheses are not intended for this registry and descriptive analysis will be conducted. Data from all clinical sites are intended to be pooled for analysis. It is possible that sub-analyses may be conducted to demonstrate VeriSight guidance for target intervention types in structural heart and electrophysiology procedures.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 years of age and willing to provide written, dated and signed, informed consent
  • Scheduled for a procedure that is within the scope of clinical indication for VeriSight per Instructions for Use (IFU)

排除标准

  • Contraindicated for ICE catheter placement or patient considerations that make placement of VeriSight not technically feasible
  • If alternate access (as needed instead of femoral) is not viable
  • Known contraindicated conditions include sepsis, major coagulation abnormalities, presence of any intracardiac thrombus, presence of class IV angina or heart failure, deep vein thrombosis, or significant peripheral vascular disease.

结局指标

主要结局

Technical Success

时间窗: During procedure

Investigator's assessment (Y/N) on successful delivery of VeriSight to the target intracardiac position and sustained device operation during the procedure

Imaging Success

时间窗: During procedure

Adequate image quality via Likert scale ( Acceptable or better) as determined by the investigator

Clinical Success

时间窗: During procedure

Investigator's assessment (Y/N) on adequacy of VeriSight imaging for visualization of major cardiac structures, and guiding procedural intervention, and ability to detect/ assess intra-procedural complications.

Number of Participants With Device-related Adverse Event Detection

时间窗: Procedure through 48 hours or discharge, whichever is earlier

Detect device-related adverse events periprocedural through discharge or ≤48 hours post-procedure, whichever is earlier.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验